Clinical Trial Update: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 study evaluating AK104 with placebo plus AK109 with placebo and paclitaxel in gastric or gastroesophageal junction adenocarcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric and Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK109 (AK109)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Akeso | Conditions: Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING